Sustained complete molecular remission after imatinib discontinuation due to severe aplastic anemia.
Hernández-Boluda
Juan-Carlos
JC
Collado
María
M
Roda
Desamparados
D
Amat
Paula
P
Tormo
Mar
M
Marugán
Isabel
I
D000368:Aged; D018712:Analgesics, Non-Narcotic / Q000627:therapeutic use; D000741:Anemia, Aplastic / Q000139:chemically induced*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001549:Benzamides; D016572:Cyclosporine / Q000627:therapeutic use; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D009181:Mycoses / Q000188:drug therapy; D010879:Piperazines / Q000009:adverse effects*; D011743:Pyrimidines / Q000009:adverse effects*; D012074:Remission Induction; D012141:Respiratory Tract Infections / Q000188:drug therapy
D018712:Analgesics, Non-Narcotic; D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D016572:Cyclosporine; D000068877:Imatinib Mesylate